Pharmaceutical Regulation, Healthcare Cost Reduction and Price Controls
First written in FY2023. 1 of 2 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
47 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「Prescription drugs are affected by regulations governing public health insurance systems and drug pricing in Japan and other countries. Japan continues to implement measures to control healthcare costs, and drug prices may be restrained by administrative policies concerning healthcare and health insurance, including annual revisions to the official drug price standard and promotion of generic drug use, which could adversely affect the Company’s operating results and financial position.」
The Company reiterates the risk that post-approval regulation, drug price controls, healthcare cost-reduction policies and overseas pricing pressure could affect results and royalty income, and also refers to measures such as the U.S. Inflation Reduction Act. - FY2023First statedAnnual report
「Prescription drugs are affected by regulations governing public health insurance systems and drug pricing in Japan and other countries. Japan continues to implement measures to control healthcare costs, and drug prices may be restrained by administrative policies concerning healthcare and health insurance, including annual revisions to the official drug price standard and promotion of generic drug use, which could adversely affect the Company’s operating results and financial position.」
Post-approval regulation, drug price controls, healthcare cost-reduction policies and overseas pricing pressure could affect the business, results and royalty income.